The present invention relates to porous membranes suitable for covering medical implants such as stents for intravascular delivery, implants covered with such membranes and methods for making the porous membranes.
Covered stents for implantation into a body vessel, duct or lumen generally include a stent and a cover attached to the stent. A porous structure of the cover, depending on the porosity, may enhance tissue ingrowth after the covered stent has been implanted. A porous structure affixed to an implantable device also may serve as a reservoir for bioactive components and/or reduce embolization by trapping thrombus against a vessel wall.
Porous membranes for use in medical devices are known in the art. For example, U.S. Pat. No. 4,759,757 to Pinchuk describes the formation of a porous membrane by leaching water soluble inorganic salts incorporated into the membrane to create pores where the salt crystals were initially located. U.S. Pat. No. 6,540,776 to Sanders Millare et al. describes a perforated membrane in which a pattern of interstices is created by removing material, for example, by laser cutting. The foregoing manufacturing methods require at least two process steps to form a porous membrane.
One step processes for forming porous membranes also are known in the art, for example, using spinning techniques. U.S. Patent Application Publication No. 20040051201 to Greenhalgh et al. describes an electrospinning process in which a membrane is formed from a plurality of randomly-oriented, intertangled, non-woven fibrils.
Spinning techniques that produce less random, but non-uniform membranes, also are known. For example, U.S. Pat. No. 4,475,972 to Wong describes a porous polymeric material made by a process in which polymeric fibers are wound on a mandrel in multiple overlying layers. The fibers contain unevaporated solvent when deposited in contact with one another, so that upon evaporation of the solvent the fibers bond together. The fibers laid in one traverse are wound on the mandrel parallel to each other and at an angle with respect to the axis of the mandrel. In the next traverse, the angle of winding is reverse to the previous angle, so that the fibers crisscross each other in multiple layers to form the porous structure.
U.S. Pat. No. 4,738,740 to Pinchuk et al. describes a spinning method similar to that of Wong and further comprising intermittently applying a electrostatic charge to ensure reattachment of broken fibers to the mandrel. U.S. Pat. No. 5,653,747 to Dereume describes a vascular graft with an expandable coating produced by the spinning technique of Wong and having pores that open when the tubular support member expands.
All of the foregoing spinning processes suffer from an inability to tightly control the pore size and pore pattern of the resulting membranes. More specifically, lateral deviation of the fibers using previously known spinning techniques has resulted in unsteady collocation of the fibers and the need to deposit multiple layers to ensure adequate coverage. Consequently, previously-known techniques produce either stiff membranes formed of multiple layers and unsatisfactory porosity, or porous, elastic membranes with insufficient strength.
In view of the foregoing, it would be desirable to provide membranes having controlled porosity, pore pattern and pore distribution.
It further would be desirable to provide a one step manufacturing process to produce membranes having controlled porosity, pore pattern and pore distribution.
It still further would be desirable to provide a one step manufacturing process to produce membranes having controlled porosity and/or pore pattern wherein the membrane includes a bioactive substance that may be eluted from the membrane after implantation.
It also would be desirable to provide manufacturing processes to produce membranes having the desired porosity, pattern and distribution characteristics for use in medical implants.
In view of the foregoing, it is an object of the present invention to provide membranes for use in medical implants having controlled porosity, pore pattern and pore distribution.
It is another object of this invention to provide a one step manufacturing process to produce membranes having controlled porosity, pore pattern and pore distribution.
It is a further object of the present invention to provide a one step manufacturing process to produce membranes having controlled porosity and/or pore pattern wherein the membrane includes a bioactive substance that may be eluted from the membrane after implantation.
It is also an object of this invention to provide manufacturing processes to produce membranes having the desired porosity, pattern and distribution characteristics for use in medical implants.
These and other objects of the present invention are accomplished by providing a membrane comprising a plurality of fibers that are deposited onto a substrate with a predetermined and reproducible pattern. The substrate may be either a mandrel or a surface of an implantable device, such as a stent. In a preferred embodiment, the fibers comprise a polymer that is sufficiently elastic and robust that the membrane follows the movements of the stent from loading onto a stent delivery system to deployment and implantation, without adversely affecting the performance of the membrane of the stent.
In a preferred embodiment, the membrane is formed using a computer-controller substrate that moves in a precisely controlled and reproducible manner. The polymer used to form the fibers, e.g., a polyurethane or a copolymer thereof, is dissolved in a solvent and extruded through one or more extrusion heads onto a moving substrate. By moving the extrusion head back and forth with a specific velocity along the axis of the substrate, specific filament angles or patterns may be deposited. In accordance with one aspect of the present invention, the number of passes, substrate shape and motion and extrusion head speed and material flow are controlled to provide a predetermined fiber diameter that is deposited to produce desired membrane properties, such as pore size and density.
The membrane may either be fixed on the exterior surface of an implantable device, such as a stent, on the interior surface or both. Where an exterior covering is desired, the membrane may be directly deposited on the implantable device. Alternatively, the covering may be deposited on a mandrel to form a separate component, and then affixed to the implantable device in a later manufacturing step.
In accordance with another aspect of the present invention, the membrane may comprise composite fibers having a viscous sheath co-extruded around a solid core component, or alternatively may comprise co-extruded viscous components. In this manner, a membrane may be created wherein the individual fibers are loaded with a desired bioactive agent, such as a drug, that elutes from the matrix of the membrane without resulting in substantial degradation of the mechanical properties of the membrane.
Methods of manufacturing covered implantable medical devices including the porous membranes of the present invention also are provided.
Further features of the invention, its nature and various advantages will be more apparent from the accompanying drawings and the following detailed description of the preferred embodiments, in which:
The present invention generally relates to medical implants, such as stents, having a porous membrane and the methods of making such membranes and medical implants. In accordance with the present invention, polymer membranes are provided that have well-defined pores based on a controlled deposition of fibers onto a substrate. In this manner a permeable membrane having a predetermined pore size and distribution may be obtained.
Acute as well as late embolization are a significant threat during and after intravascular interventions such as stenting in saphenous vein grafts (SVG) and carotid arteries, where released particles can lead to major cardiac attacks or strokes, respectively. Covered stents for treatment of atherosclerotic lesions constructed according to the present invention comprise a porous membrane bonded to an exterior surface, and interior surface, or both, of a stent. Advantageously, the covered stent of the present invention may serve both to reduce embolization during an interventional procedure and prevent late embolization by tethering emboli and particles to the vessel wall.
The inventive membrane may be engineered to provide any of a number of design properties, including: single and multi-component material composition; loading of one or more physiological (bioactive) substances into the polymer matrix; predetermined isotropic or an-isotropic mechanical properties; and predetermined pore geometry.
In accordance with the principles of the present invention, polymeric material is deposited onto a computer-controlled movable substrate. Controlling the relative location and motion of the material source with regard to the deposition location on the substrate and process parameters, such as material flow and viscosity of the deposited material, permits generation of a multitude of different patterns for the membrane.
The porous membrane of the present invention is sufficiently strong and flexible for use in medical devices, and preferably comprises steps of extruding a continuous fiber-forming biocompatible polymeric material through a reciprocating extrusion head onto a substrate to form an elongated fiber. The fiber is deposited on the substrate in a predetermined pattern in traces having a width of from 5 to 500 micrometers, adjacent traces being spaced apart from each other a distance of between 0 and 500 micrometers.
Preferably, the fibers have a predetermined viscous creep that allows adjacent traces to bond to one another at predetermined contact points upon deposition. The number of overlapping or crossing fibers generally should be less than 5, preferably less than 4, and most preferably 1 or 2. When cured, the biocompatible material provides a stable, porous membrane.
Referring to
Apparatus 10 permits highly-localized deposition of the extrudate with four degrees of freedom onto a substrate to form a membrane. The degrees of freedom are: z—the longitudinal motion of substrate 16 relative to extrusion head 15; φ—the angular movement of substrate 16 relative to extrusion head 15; r—the distance between extrusion head 15 and substrate 16; and θ—the pivotal angle of extrusion head 15. The polymer strands 17 may be deposited onto the substrate under computer control to form any of the patterns described herein below.
In a preferred embodiment, the substrate comprises a rotating mandrel. Polymer is extruded through reciprocating extrusion head 15 representing the first degree of freedom z, and with a controlled distance between the extrusion head and substrate 16, representing the second degree of freedom r. Preferably, the distance between the extrusion head and substrate is between 0 to 50 mm, and more preferably between 0.5 and 20 mm. As the polymer is deposited onto the substrate, the substrate is rotated through a predetermined angle φ, corresponding to the third degree of freedom. In this manner, fibers 17 extruded from extrusion head 15 form a two-dimensional membrane on substrate 16. In addition, by pivoting the extrusion head along its vertical axis, fourth degree of freedom θ may be employed, thus making it possible to deposit more than one filament simultaneously while maintaining a set inter-fiber distance.
The four degrees of freedom discussed above may be independently controlled and if needed, synchronized, to attain a spatial resolution of material deposition having an order of magnitude of microns or higher. Optionally, the second degree of freedom r may be fixed if stable polymer deposition has been achieved. The fourth degree of freedom is not required when extruding only one filament.
Extrusion head 15 may have one or more outlets to deposit an extruded polymer fiber onto substrate 16 in traces having an inter-trace distance ranging between 0 to 1000 micrometers. The width of the individual trace (corresponding to the fiber width) may vary between 5 to 500 micrometers, and more preferably is in the range of 10 to 200 micrometers. Pore size is a function of trace width and inter-trace distance and may be selected by selection of these variables from between 0 (i.e., a tight covering) to 200 micrometers (i.e., to form a filter or tether to trap emboli against a vessel wall). Due to the precise control of fiber deposition, it is possible to create a membrane with desired porosity, strength and flexibility with a very small number of overlapping traces or crossing traces. The number of overlapping or crossing traces in the membrane of the present invention generally should be less than 5, preferably less than 4, and most preferably 1 to 2.
The biocompatible polymer is liquefied either by dissolving the biocompatible material in solvents or by thermally melting the biocompatible material, or both. The viscosity of the liquefied material determines the viscous creep properties and thus final pore size and inter-pore distance when the material is deposited on the substrate. Preferably, the viscous creep is controlled so that desired geometrical and physical properties are met upon deposition. By controlling the viscosity and amount of the deposited material on the substrate and consequently the viscous creep of the polymer before curing, the specified inter-pore distance, pore width and inter-fiber bonding may be achieved. Alternatively, the substrate may be heated to facilitate relaxation and/or curing of the trace width after deposition on the substrate.
Viscosity also may be controlled by adjustment of the distance r of extrusion head 15 relative to substrate 16, the concentration of the solvent in extrudate 14 and/or the heating temperature, ambient pressure, and extrusion parameters. With the viscous creep of the fibers being appropriately controlled, the traces deposited on the substrate will bond to one another at predetermined contact points upon deposition.
A specified pore size of the membrane may be achieved by, but is not limited to, lateral deposition distance between two adjacent material traces, extrusion parameters, and/or extrusion head outlet diameters and extrusion pressure. The latter two parameters also affect the fiber diameter, thus in combination with the fiber deposition pattern selected, permit selection and control of the mechanical properties of the membrane.
Suitable biocompatible materials include but are not limited to polyurethane and copolymers thereof, silicone polyurethane copolymer, polypropylene and copolymers thereof, polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, PTFE and copolymers thereof. Preferred materials for forming membranes of the present invention are polyurethane and copolymers thereof. The polymers may in addition include any biologically active substance having desired release kinetics upon implantation into a patient's body.
Referring now to
Once the longitudinal fibers have been deposited on the substrate, the substrate is rotated 360° while the extrusion head is indexed along the length of the substrate, thereby forming a regular pattern of square or rectangular pores having a predetermined size. Alternatively, if extrusion head 15 is provided with multiple outlets, multiple parallel fibers may be deposited in a single longitudinal pass.
More generally, apparatus 10 may be used to deposit one or more traces of a biocompatible material on substrate 16 while extrusion head 15 is reciprocated along the length of the substrate. An extrusion head having multiple outlets permit the deposition of multiple filaments on the substrate during a single translation of the extrusion head or rotation of the substrate. All translational and rotational motions of the components of apparatus 10 are individually or synchronously controlled by computer 13, thus permitting the membrane to be configured with any desired pattern.
As discussed above with respect to
In accordance with one aspect of the present invention, extrusion is performed with chemically or thermally liquefied material, or both. The viscosity of the extrudate may be controlled by the concentration of the solvent, by enhancing evaporation of the solvent from the deposited material trace by means of heating the substrate, by varying the distance r between the extrusion head and the substrate, or by adjusting the extrusion temperature of the material so that a well-defined viscous creep of the material occurs after deposition onto the substrate.
Adjustment of the viscous creep allows fusion of the traces at contact points and thus formation of a two-dimensional membrane having desired mechanical strength characteristics. By appropriately setting these parameters accurate material deposition may be achieved with reduced lateral aberrations of the filaments compared to previously-known membrane manufacturing techniques.
As will of course be understood, the diameter of the substrate should be selected based upon the dimensions of the medical implant or stent to which the membrane is to be affixed. For example, the diameter may be selected based upon the expanded configuration of the medical implant or stent. The implant to be covered may be balloon-expandable or self-expandable. In a preferred embodiment, the implant is a self-expandable stent comprising a superelastic material such as a nickel-titanium alloy.
Referring to
Alternatively, the membrane may be deposited on a mandrel and after curing may be bonded in a separate step to the medical implant. In the latter case, thermal drying and/or evaporation of the solvent cures the biocompatible material while on the substrate. Once the membrane has cured sufficiently so that the mechanical properties of the membrane permit it to be removed from the substrate, the membrane may be bonded to a surface of the implant using a solvent, adhesive or thermal technique. In this case, the surface of the implant may be pre-processed to optimize bonding, for example by activation of the surface, coating of the surface with liquified polymer or other appropriate treatments of the surface.
Referring now to
Multi-component fiber 41 may be deposited onto the substrate to form a two-dimensional contiguous structure. The individual components of fiber 41 may be selected to provide different characteristics to the membrane, which may employ any of the pattern designs discussed herein above. For example, core filament 42 may provide mechanical stability, while material 43 may serve as and interface to the biological environment, enhance the adhesive properties for inter-trace bonding and/or enhance bonding of the membrane to the medical implant.
Suitable materials for the core filament include but are not limited to polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, and PTFE and copolymers thereof, and metal wire or fiber glass. Suitable materials for ensheathing core filament 41 include but are not limited to polyurethane and copolymers thereof, silicone polyurethane copolymer, polypropylene and copolymers thereof, polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, PTFE and copolymers thereof.
Referring to
Suitable materials for first material 52 include but are not limited to polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, PTFE and copolymers thereof. Suitable materials for second material 53 include but are not limited to polyurethane and copolymers thereof, silicone polyurethane copolymer, polypropylene and copolymers thereof, polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, PTFE and copolymers thereof.
It should be understood that the present invention is not limited to membranes for use on stents. Rather, the membranes of the present invention may be affixed to any other medical device or implant that is brought into an intracorporal lumen for limited or extended implant durations. Such devices include vascular protection devices to filter emboli that are only transiently introduced into the body. Further applications for such porous membranes may be devices configured to be introduced into other body lumens or ducts, such as the trachea, esophagus, and biliary or urinary lumina.
While preferred illustrative embodiments of the invention are described above, it will be apparent to one skilled in the art that various changes and modifications may be made therein without departing from the invention. The appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.
The present application is a continuation-in-part of U.S. patent application Ser. No. 10/859,636, filed Jun. 3, 2004, which is a continuation of U.S. patent application Ser. No. 09/967,789, filed Sep. 28, 2001. This application also claims the benefit of priority from U.S. provisional patent application Ser. No. 60/637,495, filed Dec. 20, 2004.
Number | Name | Date | Kind |
---|---|---|---|
4475972 | Wong | Oct 1984 | A |
4580568 | Gianturco | Apr 1986 | A |
4738740 | Pinchuk et al. | Apr 1988 | A |
4743252 | Martin, Jr. et al. | May 1988 | A |
4759757 | Pinchuk | Jul 1988 | A |
4800882 | Gianturco | Jan 1989 | A |
4907336 | Gianturco | Mar 1990 | A |
5015253 | MacGregor | May 1991 | A |
5041126 | Gianturco | Aug 1991 | A |
5059211 | Stack et al. | Oct 1991 | A |
5102417 | Palmaz | Apr 1992 | A |
5104404 | Wolff | Apr 1992 | A |
5116360 | Pinchuk et al. | May 1992 | A |
5122154 | Rhodes | Jun 1992 | A |
5133732 | Wiktor | Jul 1992 | A |
5147370 | McNamara et al. | Sep 1992 | A |
5163951 | Pinchuk et al. | Nov 1992 | A |
5171262 | MacGregor | Dec 1992 | A |
5221261 | Termin et al. | Jun 1993 | A |
5282823 | Schwartz et al. | Feb 1994 | A |
5292331 | Boneau | Mar 1994 | A |
5314444 | Gianturco | May 1994 | A |
5370683 | Fontaine | Dec 1994 | A |
5378239 | Termin et al. | Jan 1995 | A |
5380299 | Fearnot et al. | Jan 1995 | A |
5421955 | Lau et al. | Jun 1995 | A |
5443458 | Eury | Aug 1995 | A |
5443496 | Schwartz et al. | Aug 1995 | A |
5449373 | Pinchasik et al. | Sep 1995 | A |
5476508 | Amstrup | Dec 1995 | A |
5496277 | Termin et al. | Mar 1996 | A |
5514154 | Lau et al. | May 1996 | A |
5527354 | Fontaine et al. | Jun 1996 | A |
5556414 | Turi | Sep 1996 | A |
5569295 | Lam | Oct 1996 | A |
5591197 | Orth et al. | Jan 1997 | A |
5591224 | Schwartz et al. | Jan 1997 | A |
5593417 | Rhodes | Jan 1997 | A |
5593442 | Klein | Jan 1997 | A |
5603721 | Lau et al. | Feb 1997 | A |
5609606 | O'Boyle | Mar 1997 | A |
5628788 | Pinchuk | May 1997 | A |
5630829 | Lauterjung | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5649952 | Lam | Jul 1997 | A |
5651174 | Schwartz et al. | Jul 1997 | A |
5653747 | Dereume | Aug 1997 | A |
5670161 | Healy et al. | Sep 1997 | A |
5674242 | Phan et al. | Oct 1997 | A |
5674277 | Freitag | Oct 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5695516 | Fischell et al. | Dec 1997 | A |
5697971 | Fischell et al. | Dec 1997 | A |
5700285 | Myers et al. | Dec 1997 | A |
5707386 | Schnepp-Pesch et al. | Jan 1998 | A |
5707388 | Lauterjung | Jan 1998 | A |
5709703 | Lukic et al. | Jan 1998 | A |
5709713 | Evans et al. | Jan 1998 | A |
5716393 | Lindenburg et al. | Feb 1998 | A |
5723003 | Winston et al. | Mar 1998 | A |
5723004 | Dereume et al. | Mar 1998 | A |
5728158 | Lau et al. | Mar 1998 | A |
5733303 | Israel et al. | Mar 1998 | A |
5735892 | Myers et al. | Apr 1998 | A |
5735893 | Lau et al. | Apr 1998 | A |
5735897 | Buirge | Apr 1998 | A |
5738817 | Danforth et al. | Apr 1998 | A |
5741325 | Chaikof et al. | Apr 1998 | A |
5741327 | Frantzen | Apr 1998 | A |
5743874 | Fischell et al. | Apr 1998 | A |
5749880 | Banas et al. | May 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5755772 | Evans et al. | May 1998 | A |
5755774 | Pinchuk | May 1998 | A |
5755781 | Jayaraman | May 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5776161 | Globerman | Jul 1998 | A |
5776181 | Lee et al. | Jul 1998 | A |
5776183 | Kanesaka et al. | Jul 1998 | A |
5800526 | Anderson et al. | Sep 1998 | A |
5807404 | Richter | Sep 1998 | A |
5810868 | Lashinski et al. | Sep 1998 | A |
5810870 | Myers et al. | Sep 1998 | A |
5810872 | Kanesaka et al. | Sep 1998 | A |
5814063 | Freitag | Sep 1998 | A |
5817126 | Imran | Oct 1998 | A |
5824037 | Fogarty et al. | Oct 1998 | A |
5824045 | Alt | Oct 1998 | A |
5824048 | Tuch | Oct 1998 | A |
5824054 | Khosravi et al. | Oct 1998 | A |
5824059 | Wijay | Oct 1998 | A |
5827321 | Roubin et al. | Oct 1998 | A |
5836964 | Richter et al. | Nov 1998 | A |
5836966 | St. Germain | Nov 1998 | A |
5843120 | Israel et al. | Dec 1998 | A |
5843158 | Lenker et al. | Dec 1998 | A |
5843161 | Solovay | Dec 1998 | A |
5843164 | Frantzen et al. | Dec 1998 | A |
5846247 | Unsworth et al. | Dec 1998 | A |
5853419 | Imran | Dec 1998 | A |
5855598 | Pinchuk | Jan 1999 | A |
5855600 | Alt | Jan 1999 | A |
5860999 | Schnepp-Pesch et al. | Jan 1999 | A |
5861027 | Trapp | Jan 1999 | A |
5868781 | Killion | Feb 1999 | A |
5871538 | Dereume | Feb 1999 | A |
5876449 | Starck et al. | Mar 1999 | A |
5876450 | Johlin, Jr. | Mar 1999 | A |
5895406 | Gray et al. | Apr 1999 | A |
5897589 | Cottenceau et al. | Apr 1999 | A |
5922021 | Jang | Jul 1999 | A |
5928248 | Acker | Jul 1999 | A |
5938682 | Hojeibane et al. | Aug 1999 | A |
5948018 | Dereume et al. | Sep 1999 | A |
5954743 | Jang | Sep 1999 | A |
5968091 | Pinchuk et al. | Oct 1999 | A |
5980552 | Pinchasik et al. | Nov 1999 | A |
5984965 | Knapp et al. | Nov 1999 | A |
6017365 | Von Oepen | Jan 2000 | A |
6019789 | Dinh et al. | Feb 2000 | A |
6027526 | Limon et al. | Feb 2000 | A |
6033433 | Ehr et al. | Mar 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6033435 | Penn et al. | Mar 2000 | A |
6039756 | Jang | Mar 2000 | A |
6048361 | Von Oepen | Apr 2000 | A |
6059811 | Pinchasik et al. | May 2000 | A |
6068656 | Von Oepen | May 2000 | A |
6071308 | Ballou et al. | Jun 2000 | A |
6086610 | Duerig et al. | Jul 2000 | A |
6099561 | Alt | Aug 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6113627 | Jang | Sep 2000 | A |
6117165 | Becker | Sep 2000 | A |
6117535 | Szycher et al. | Sep 2000 | A |
6123721 | Jang | Sep 2000 | A |
6132460 | Thompson | Oct 2000 | A |
6165212 | Dereume et al. | Dec 2000 | A |
6174326 | Kitakoa et al. | Jan 2001 | B1 |
6179868 | Burpee et al. | Jan 2001 | B1 |
6190403 | Fischell et al. | Feb 2001 | B1 |
6193744 | Ehr et al. | Feb 2001 | B1 |
6193747 | Von Oepen | Feb 2001 | B1 |
6200334 | Jang | Mar 2001 | B1 |
6200335 | Igaki | Mar 2001 | B1 |
6203569 | Wijay | Mar 2001 | B1 |
6231598 | Berry et al. | May 2001 | B1 |
6231600 | Zhong | May 2001 | B1 |
6241762 | Shanley | Jun 2001 | B1 |
6253443 | Johnson | Jul 2001 | B1 |
6258116 | Hojeibane | Jul 2001 | B1 |
6261318 | Lee et al. | Jul 2001 | B1 |
6264688 | Herklotz et al. | Jul 2001 | B1 |
6264690 | Von Oepen | Jul 2001 | B1 |
6270524 | Kim | Aug 2001 | B1 |
6273913 | Wright et al. | Aug 2001 | B1 |
6299604 | Ragheb et al. | Oct 2001 | B1 |
6299635 | Frantzen | Oct 2001 | B1 |
6325825 | Kula et al. | Dec 2001 | B1 |
6331189 | Wolinsky et al. | Dec 2001 | B1 |
6332089 | Acker et al. | Dec 2001 | B1 |
6340366 | Wijay | Jan 2002 | B2 |
6348065 | Brown et al. | Feb 2002 | B1 |
6377835 | Schoenberg et al. | Apr 2002 | B1 |
6395020 | Ley et al. | May 2002 | B1 |
6436132 | Patel et al. | Aug 2002 | B1 |
6451049 | Vallana et al. | Sep 2002 | B2 |
6485508 | McGuinness | Nov 2002 | B1 |
6488702 | Besselink | Dec 2002 | B1 |
6491718 | Ahmad | Dec 2002 | B1 |
6503272 | Duerig et al. | Jan 2003 | B2 |
6506211 | Skubitz et al. | Jan 2003 | B1 |
6508834 | Pinchasik et al. | Jan 2003 | B1 |
6540776 | Sanders Millare et al. | Apr 2003 | B2 |
6558415 | Thompson | May 2003 | B2 |
6572646 | Boylan et al. | Jun 2003 | B1 |
6589276 | Pinchasik et al. | Jul 2003 | B2 |
6602285 | Von Oepen et al. | Aug 2003 | B1 |
6607554 | Dang et al. | Aug 2003 | B2 |
6616689 | Ainsworth et al. | Sep 2003 | B1 |
6624097 | Martin et al. | Sep 2003 | B2 |
D481139 | Seibold et al. | Oct 2003 | S |
6629994 | Gomez et al. | Oct 2003 | B2 |
6679911 | Burgermeister | Jan 2004 | B2 |
6682554 | Oepen et al. | Jan 2004 | B2 |
6723119 | Pinchasik et al. | Apr 2004 | B2 |
6730252 | Teoh et al. | May 2004 | B1 |
6740114 | Burgermeister | May 2004 | B2 |
6749629 | Hong et al. | Jun 2004 | B1 |
6755856 | Fierens et al. | Jun 2004 | B2 |
6776794 | Hong et al. | Aug 2004 | B1 |
6786922 | Schaeffer | Sep 2004 | B2 |
6790227 | Burgermeister | Sep 2004 | B2 |
6796999 | Pinchasik | Sep 2004 | B2 |
6821292 | Pazienza et al. | Nov 2004 | B2 |
6846323 | Yip et al. | Jan 2005 | B2 |
6875228 | Pinchasik et al. | Apr 2005 | B2 |
6881222 | White et al. | Apr 2005 | B2 |
6913619 | Brown et al. | Jul 2005 | B2 |
6916336 | Patel et al. | Jul 2005 | B2 |
6929660 | Ainsworth et al. | Aug 2005 | B1 |
6942689 | Majercak | Sep 2005 | B2 |
6955686 | Majercak et al. | Oct 2005 | B2 |
6998060 | Tomonto | Feb 2006 | B2 |
7029493 | Majercak et al. | Apr 2006 | B2 |
7060093 | Dang et al. | Jun 2006 | B2 |
7128756 | Lowe et al. | Oct 2006 | B2 |
7141062 | Pinchasik et al. | Nov 2006 | B1 |
7329277 | Addonizio et al. | Feb 2008 | B2 |
7520892 | Ainsworth et al. | Apr 2009 | B1 |
7625398 | Clifford et al. | Dec 2009 | B2 |
20010027339 | Boatman et al. | Oct 2001 | A1 |
20010049549 | Boylan et al. | Dec 2001 | A1 |
20020019660 | Gianotti et al. | Feb 2002 | A1 |
20020035394 | Fierens et al. | Mar 2002 | A1 |
20020065549 | White et al. | May 2002 | A1 |
20020107560 | Richter | Aug 2002 | A1 |
20020111669 | Pazienza et al. | Aug 2002 | A1 |
20020151964 | Smith et al. | Oct 2002 | A1 |
20020169499 | Zilla et al. | Nov 2002 | A1 |
20030055487 | Calisse | Mar 2003 | A1 |
20030083736 | Brown et al. | May 2003 | A1 |
20030114918 | Garrison et al. | Jun 2003 | A1 |
20030120334 | Gerbeding | Jun 2003 | A1 |
20040051201 | Greenhalgh et al. | Mar 2004 | A1 |
20040093073 | Lowe et al. | May 2004 | A1 |
20040102836 | Fischell et al. | May 2004 | A1 |
20040126405 | Sahatjian et al. | Jul 2004 | A1 |
20040193250 | Von Oepen et al. | Sep 2004 | A1 |
20040230293 | Yip et al. | Nov 2004 | A1 |
20040236407 | Fierens et al. | Nov 2004 | A1 |
20040243220 | Gianotti et al. | Dec 2004 | A1 |
20050004650 | Oepen et al. | Jan 2005 | A1 |
20050004651 | Von Oepen et al. | Jan 2005 | A1 |
20050004655 | Von Oepen et al. | Jan 2005 | A2 |
20050004658 | Oepen et al. | Jan 2005 | A1 |
20050004659 | Von Oepen et al. | Jan 2005 | A1 |
20050004662 | Von Oepen et al. | Jan 2005 | A1 |
20050043777 | Von Oepen et al. | Feb 2005 | A1 |
20050043778 | Von Oepen et al. | Feb 2005 | A1 |
20050075716 | Yan | Apr 2005 | A1 |
20050222671 | Schaeffer et al. | Oct 2005 | A1 |
20060015173 | Clifford et al. | Jan 2006 | A1 |
20060106452 | Niermann | May 2006 | A1 |
20060142844 | Lowe et al. | Jun 2006 | A1 |
20060184232 | Gianotti et al. | Aug 2006 | A1 |
20060206195 | Calisse | Sep 2006 | A1 |
20060247759 | Burpee et al. | Nov 2006 | A1 |
20070021827 | Lowe et al. | Jan 2007 | A1 |
20070021834 | Young et al. | Jan 2007 | A1 |
20070135891 | Schneider | Jun 2007 | A1 |
20070179593 | Fierens et al. | Aug 2007 | A1 |
20070179601 | Fierens et al. | Aug 2007 | A1 |
20070213800 | Fierens et al. | Sep 2007 | A1 |
20070299505 | Gregorich et al. | Dec 2007 | A1 |
20080294239 | Casey | Nov 2008 | A1 |
20080294240 | Casey | Nov 2008 | A1 |
20090163992 | Osman et al. | Jun 2009 | A1 |
20090163996 | Bregulla | Jun 2009 | A1 |
20090163997 | Casey | Jun 2009 | A1 |
20090163998 | Casey | Jun 2009 | A1 |
Number | Date | Country |
---|---|---|
2309079 | Nov 2004 | CA |
0699451 | Mar 1996 | EP |
0709067 | May 1996 | EP |
0808614 | Nov 1997 | EP |
0928605 | Jul 1999 | EP |
0950386 | Oct 1999 | EP |
0983753 | Mar 2000 | EP |
1042997 | Oct 2000 | EP |
1095631 | May 2001 | EP |
1516600 | Mar 2005 | EP |
2774279 | Aug 1999 | FR |
2344053 | May 2000 | GB |
7-24072 | Jan 1995 | JP |
08-206226 | Aug 1996 | JP |
09-010318 | Jan 1997 | JP |
10-328216 | Dec 1998 | JP |
11-299901 | Feb 1999 | JP |
2000312721 | Nov 2000 | JP |
WO9117789 | Nov 1991 | WO |
WO9621404 | Jul 1996 | WO |
WO9625124 | Aug 1996 | WO |
WO9712563 | Apr 1997 | WO |
WO9712564 | Apr 1997 | WO |
WO9714375 | Apr 1997 | WO |
WO9832412 | Jul 1998 | WO |
WO9847447 | Oct 1998 | WO |
WO9907308 | Feb 1999 | WO |
WO9917680 | Apr 1999 | WO |
WO9923976 | May 1999 | WO |
WO9938456 | Aug 1999 | WO |
WO9938458 | Aug 1999 | WO |
WO9939660 | Aug 1999 | WO |
WO9949928 | Oct 1999 | WO |
WO0013611 | Mar 2000 | WO |
WO0032241 | Jun 2000 | WO |
WO0045744 | Aug 2000 | WO |
WO0053119 | Sep 2000 | WO |
WO0101885 | Jan 2001 | WO |
WO0182835 | Nov 2001 | WO |
WO0226164 | Apr 2002 | WO |
WO02064061 | Aug 2002 | WO |
WO02064065 | Aug 2002 | WO |
WO02094127 | Nov 2002 | WO |
WO03009779 | Feb 2003 | WO |
WO03057076 | Jul 2003 | WO |
WO2004087015 | Oct 2004 | WO |
WO2006055533 | May 2006 | WO |
WO2006066886 | Jun 2006 | WO |
WO2006099449 | Sep 2006 | WO |
WO2008042618 | Apr 2008 | WO |
WO2008142566 | Nov 2008 | WO |
WO2009046973 | Apr 2009 | WO |
WO2009080326 | Jul 2009 | WO |
WO2009080327 | Jul 2009 | WO |
Number | Date | Country | |
---|---|---|---|
20060175727 A1 | Aug 2006 | US |
Number | Date | Country | |
---|---|---|---|
60637495 | Dec 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09967789 | Sep 2001 | US |
Child | 10859636 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10859636 | Jun 2004 | US |
Child | 11313110 | US |